Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

50.87 +1.20 (+2.42%)

Streaming Delayed Price Updated: 11:45 AM EDT, Jul 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Where Will Novo Nordisk Stock Be in 3 Years? ↗

Today 9:11 EDT

Trailing a powerful competitor, Novo Nordisk could stay firmly in second place for a good while.

Via The Motley Fool

Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors? ↗

July 24, 2026

Novo Nordisk is accusing Eli Lilly of deceptive advertising about GLP-1 drugs.

Via The Motley Fool

Topics Lawsuit

2 Top Growth Stocks to Buy Right Now Without Any Hesitation ↗

July 24, 2026

There are plenty of reasons to love these companies.

Via The Motley Fool

3 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now ↗

July 23, 2026

With yields like this, these undervalued tickers aren't apt to remain this cheap forever.

Via The Motley Fool

Topics Lawsuit

"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What That Means for Both Stocks. ↗

July 21, 2026

Novo Nordisk is also demanding that Eli Lilly pull its ads and pay damages.

Via The Motley Fool

Topics Lawsuit

Novo Nordisk's Dividend Story Is Changing -- Here's What Investors Are Missing ↗

July 21, 2026

Novo Nordisk is offering an attractive 3.5% yield backed by a business where volume is the new focus.

Via The Motley Fool

Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market? ↗

July 20, 2026

It is definitely a strong contender.

Via The Motley Fool

Topics Intellectual Property

Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1 ↗

July 18, 2026

Viking's latest program seeks to push the envelope in weight loss efficacy.

Via The Motley Fool

The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss ↗

July 17, 2026

There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.

Via The Motley Fool

Topics Intellectual Property

Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win ↗

July 17, 2026

Novo Nordisk is finally getting one up on its biggest rival.

Via The Motley Fool

3 High-Yield Dividend Stocks to Buy and Hold ↗

July 17, 2026

All three can be bought on the dip.

Via The Motley Fool

Topics Intellectual Property

This GLP-1 Stock Could Double by 2030. Here's Why ↗

July 16, 2026

Investors need to ask tough questions before initiating a position in this biotech company.

Via The Motley Fool

2 Beaten-Down GLP-1 Stocks to Buy on the Dip ↗

July 15, 2026

Don't wait until clinical milestones send their share prices soaring.

Via The Motley Fool

Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market? ↗

July 14, 2026

Eyes are on the rollout of Lilly's new weight loss pill.

Via The Motley Fool

3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026 ↗

July 11, 2026

This is the list for you if you are looking for dividend stocks with attractive yields and well-supported dividends.

Via The Motley Fool

Should You Buy Eli Lilly Stock? Here's My Honest Take. ↗

July 11, 2026

There are good reasons to invest in Lilly and to hold off.

Via The Motley Fool

Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market? ↗

July 10, 2026

So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off.

Via The Motley Fool

Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week ↗

July 10, 2026

An accelerated approval for Agios' key drug to treat sickle cell disease appears to be on the cards.

Via The Motley Fool

Is It Too Late to Buy Eli Lilly? ↗

July 08, 2026

The stock has soared 400% in recent years.

Via The Motley Fool

Prediction: Eli Lilly Stock Will Hit This Price by the End of 2026 ↗

July 08, 2026

Eli Lilly's next leg of growth may have less to do with how well its weight loss drugs work and more to do with how many people can finally get them.

Via The Motley Fool

Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom ↗

July 07, 2026

Don't sleep on these medical device leaders.

Via The Motley Fool

Topics Supply Chain

3 Reasons to Buy Novo Nordisk Stock ↗

July 07, 2026

The stock is down, but it isn't out yet.

Via The Motley Fool

U.S. Healthcare Spending Just Hit $5.7 Trillion and Continues to Grow: 2 Stocks to Buy to Profit From the Trend ↗

July 07, 2026

Good medical care will always be in high demand, which makes some healthcare stocks strong long-term picks.

Via The Motley Fool

As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner ↗

July 06, 2026

Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.

Via MarketBeat

Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years? ↗

July 06, 2026

The weight-loss market is crowded, but this company's lead drug candidate has several key advantages.

Via The Motley Fool

Could Buying Eli Lilly Stock Today Set You Up for Life? (Hint: Yes.) ↗

July 06, 2026

Lilly offers investors safety and growth.

Via The Motley Fool

How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030? ↗

July 05, 2026

This biotech might have a bright future, but it'll need to survive against the incumbents to do so.

Via The Motley Fool

Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying ↗

July 04, 2026

The stock is known to soar on good news.

Via The Motley Fool

Here's Why Viking Therapeutics Stock Surged Higher in June ↗

July 03, 2026

Investors are growing more optimistic over the company's pipeline and the initiation of a Phase 1 trial with a new drug.

Via The Motley Fool

2 Top Growth Stocks to Buy Right Now Without Hesitation ↗

June 29, 2026

These stocks are no-brainer buys.

Via The Motley Fool

Topics Economy

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novo Nordisk A/S Common Stock (NY:NVO)

Headline News about Novo Nordisk A/S Common Stock

Resources